International differences in the treatment of sepsis: Are they justified?

JAMA

Volumn 301, Issue 23, 2009, Pages 2496-2497

  Kellum, John A ^a   Uchino, Shigehiko ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; GLUCOSE; POLYMYXIN B; VASOACTIVE AGENT; ANTIINFECTIVE AGENT;

DISEASE SEVERITY; DRUG APPROVAL; EDITORIAL; EVIDENCE BASED MEDICINE; FLUID RESUSCITATION; GLYCEMIC CONTROL; HEMODYNAMICS; HEMOFILTRATION; HEMOPERFUSION; HUMAN; INTENSIVE CARE UNIT; MEAN ARTERIAL PRESSURE; MEDICAL PRACTICE; MORTALITY; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; SEPSIS; THERAPY EFFECT; VALIDATION STUDY; CLINICAL TRIAL; INTERNATIONAL COOPERATION; MEDICAL ETHICS; NOTE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; ETHICS, MEDICAL; EVIDENCE-BASED MEDICINE; HEMOPERFUSION; HUMANS; INTERNATIONALITY; POLYMYXIN B; SEPSIS;

EID: 67649219642     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.850     Document Type: Editorial

References (11)

1. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
2. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
3. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-1341.
4. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369(9564):836-843.
5. Hirasawa H, Sugai T, Ohtake Y, Oda S, Matsuda K, Kitamura N. Blood purification for prevention and treatment of multiple organ failure. World J Surg. 1996;20(4):482-486.
6. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445-2452.
7. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2):R47.
8. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock [errata in: Crit Care Med. 2004;32(6):1448 and Crit Care Med. 2004;32(10):2169-70]. Crit Care Med. 2004;32(3):858-873.
9. Finfer S, Chittock DR, Su SY, et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297.
10. Palevsky PM, Zhang JH, O'Connor TZ, et al; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7-20.
11. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/ b3.htm. Accessed May 3, 2009.